Dr. Paige is an internationally recognized leader in the area of lymphocyte development and antibody formation, with an active research program in training the immune system to recognize cancer cells. His original research is published in leading scientific journals including Nature, Science, Cell and the Journal of Experimental Medicine.

He earned a Ph.D. in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He was a Member of the Basel Institute for Immunology in Switzerland (1980-1987) before joining the Ontario Cancer Institute as a Senior Scientist in 1987.

In 1990, Dr. Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1998, he returned to the Ontario Cancer Institute to assume the role of Vice President, Research and subsequently assumed his current position of Executive Vice President, Science and Research at the UHN, which comprises four hospitals: Toronto Rehab, Toronto General Hospital, Toronto Western Hospital and Princess Margaret Cancer Centre.

A Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto, Dr. Paige is an active educator in the undergraduate, graduate and postgraduate programs of the University.

He has served on the Research Advisory Boards of the National Cancer Institute and the Arthritis Society of Canada. He is the past Chairman of the Board of the Biotechnology Commercialization Centre, which helped establish a Biotechnology Incubator in Toronto and past Chairman of BioDiscovery Toronto, a consortium of 12 Toronto-based hospitals and universities engaged in the commercialization of research discoveries. He also serves on the Boards of the Terry Fox Research Institute, The Princess Margaret Cancer Foundation, the Toronto General & Western Hospital Foundation, the Arthritis Research Foundation, the Council of Ontario Research Directors, Research Canada, the Ontario Institute for Cancer Research and the Ontario Health Research Alliance. Dr. Paige is also a co-founder and the Chairman of the Board of GEMMA Biotechnology. Its purpose is to discover and commercially develop biological response modifiers which influence the course of human disease. He was the founder and co-Director of the Shanghai-Toronto Institute for Health Science (STI), a partnership between the Shanghai Institute of Health Sciences, the Shanghai Institute of Organic Chemistry and UHN. UHN currently maintains laboratories in the Zhangjiang High Technology Park in Shanghai.